Australia’s medicines regulator has issued a safety warning over popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Saxenda, saying they could cause a rare vision disorder.
The Therapeutic Goods Administration (TGA) warned that the GLP-1 RA class of medicines have the potential to cause non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment, including blindness. There is currently no treatment for NAION.
The regulator revealed that a potential link between GLP-1 RAs and NAION was first discovered in July 2024 following a study published in JAMA Ophthalmology. The TGA conducted an independent assessment but found conflicting evidence. After seeking expert advice from the Advisory Committee on Medicines (ACM), which concluded that current evidence supports a signal for semaglutide, the TGA decided to update product information and publish safety communications.
The TGA urges any patients who experience sudden vision loss, even if only partial, to seek urgent medical attention. The affected medicines include Ozempic, Wegovy, Mounjaro, Saxenda, and Trulicity.
Article and image source: thewest.com.au
Single Mother Of Four Starts Culinary Journey At 56, Graduates As Tobago Valedictorian
WASA truck gets taste of its own medicine after getting stuck in damaged roadway
Kai Cenat Reveals Trinidad Carnival Inspired Denim Design In His Latest Fashion Collection Launch
PM releases SoE report showing 5,802 arrested and 3,552 charged over six months
What causes electricity outages? From storms and fallen lines to equipment failure and overloads, see…
16-Year-Old Shania Valentine Reported Missing in Wallerfield, Arima; Police and Hunters Search Team Urge Public